Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo

Bach Ardalan, Masato Arakawa, Doris Villacorte, Hiremagalur Jayaram, David A. Cooney

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The intratumoral content of 5-phosphoribosyl 1-pyrophosphate (PRPP) and the acitivity of the enzymes anabolizing and catabolizing the sugar phosphate were determined following i.p. administration of an ld10 dose of an l-glutamine antagonist or saline to tumor-bearing animals. Elevation of PRPP pool size following administration of l-[αS,5S]-α-amino-3-chloro-4,5-dihydro-5-isopazoleacetic acid (NSC-163501) (AT-125) was maximal at 8 hr and returned to pretreatment levels by 24 hr. In P388 leukemia, dose for dose, at 4 hr, 6-diazo-5-oxo-l-norleucine (NSC-7365) (DON) was the most potent of the l-glutamine antagonists in elevating basal PRPP pool size (507% above control) followed by AT-125 and azaserine, 300 and 100% above control respectively. Moreover, such augmentation in PRPP pool size preferentially affected P388 tumor rather than the small intestine. Following i.p. administration of ld10 doses of AT-125, DON and azaserine, the specific activities of PRPP anabolizing and catabolizing enzymes were determined. A significant inhibition of PRPP amidotransferase was demonstrated with DON and AT-125 (P <0.05), and no inhibition with azaserine. A similar modulation of PRPP pool size was demonstrated in vivo following administration of 250 mg/kg of AT-125 in mice bearing colonic adenocarcinoma lines. It was suggested that a significant increase of PRPP pool size might cause the possible synergism of a selected l-glutamine antagonist and 5-fluorouracil as reported after the appropriately scheduled administration of methotrexate and 5-fluorouracil.

Original languageEnglish (US)
Pages (from-to)1509-1513
Number of pages5
JournalBiochemical Pharmacology
Volume31
Issue number8
DOIs
StatePublished - Apr 15 1982
Externally publishedYes

Fingerprint

acivicin
Phosphoribosyl Pyrophosphate
Leukemia P388
Glutamine
Colon
Adenocarcinoma
Azaserine
Bearings (structural)
Fluorouracil
Amidophosphoribosyltransferase
Diazooxonorleucine
Tumors
Sugar Phosphates
Norleucine
Enzymes
diphosphoric acid
Methotrexate
Small Intestine
Neoplasms
Animals

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo. / Ardalan, Bach; Arakawa, Masato; Villacorte, Doris; Jayaram, Hiremagalur; Cooney, David A.

In: Biochemical Pharmacology, Vol. 31, No. 8, 15.04.1982, p. 1509-1513.

Research output: Contribution to journalArticle

Ardalan, Bach ; Arakawa, Masato ; Villacorte, Doris ; Jayaram, Hiremagalur ; Cooney, David A. / Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo. In: Biochemical Pharmacology. 1982 ; Vol. 31, No. 8. pp. 1509-1513.
@article{b94655c3be11496baf31832f724de797,
title = "Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo",
abstract = "The intratumoral content of 5-phosphoribosyl 1-pyrophosphate (PRPP) and the acitivity of the enzymes anabolizing and catabolizing the sugar phosphate were determined following i.p. administration of an ld10 dose of an l-glutamine antagonist or saline to tumor-bearing animals. Elevation of PRPP pool size following administration of l-[αS,5S]-α-amino-3-chloro-4,5-dihydro-5-isopazoleacetic acid (NSC-163501) (AT-125) was maximal at 8 hr and returned to pretreatment levels by 24 hr. In P388 leukemia, dose for dose, at 4 hr, 6-diazo-5-oxo-l-norleucine (NSC-7365) (DON) was the most potent of the l-glutamine antagonists in elevating basal PRPP pool size (507{\%} above control) followed by AT-125 and azaserine, 300 and 100{\%} above control respectively. Moreover, such augmentation in PRPP pool size preferentially affected P388 tumor rather than the small intestine. Following i.p. administration of ld10 doses of AT-125, DON and azaserine, the specific activities of PRPP anabolizing and catabolizing enzymes were determined. A significant inhibition of PRPP amidotransferase was demonstrated with DON and AT-125 (P <0.05), and no inhibition with azaserine. A similar modulation of PRPP pool size was demonstrated in vivo following administration of 250 mg/kg of AT-125 in mice bearing colonic adenocarcinoma lines. It was suggested that a significant increase of PRPP pool size might cause the possible synergism of a selected l-glutamine antagonist and 5-fluorouracil as reported after the appropriately scheduled administration of methotrexate and 5-fluorouracil.",
author = "Bach Ardalan and Masato Arakawa and Doris Villacorte and Hiremagalur Jayaram and Cooney, {David A.}",
year = "1982",
month = "4",
day = "15",
doi = "10.1016/0006-2952(82)90373-2",
language = "English (US)",
volume = "31",
pages = "1509--1513",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Effect of l-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in p388 leukemia and in murine colon adenocarcinomas in vivo

AU - Ardalan, Bach

AU - Arakawa, Masato

AU - Villacorte, Doris

AU - Jayaram, Hiremagalur

AU - Cooney, David A.

PY - 1982/4/15

Y1 - 1982/4/15

N2 - The intratumoral content of 5-phosphoribosyl 1-pyrophosphate (PRPP) and the acitivity of the enzymes anabolizing and catabolizing the sugar phosphate were determined following i.p. administration of an ld10 dose of an l-glutamine antagonist or saline to tumor-bearing animals. Elevation of PRPP pool size following administration of l-[αS,5S]-α-amino-3-chloro-4,5-dihydro-5-isopazoleacetic acid (NSC-163501) (AT-125) was maximal at 8 hr and returned to pretreatment levels by 24 hr. In P388 leukemia, dose for dose, at 4 hr, 6-diazo-5-oxo-l-norleucine (NSC-7365) (DON) was the most potent of the l-glutamine antagonists in elevating basal PRPP pool size (507% above control) followed by AT-125 and azaserine, 300 and 100% above control respectively. Moreover, such augmentation in PRPP pool size preferentially affected P388 tumor rather than the small intestine. Following i.p. administration of ld10 doses of AT-125, DON and azaserine, the specific activities of PRPP anabolizing and catabolizing enzymes were determined. A significant inhibition of PRPP amidotransferase was demonstrated with DON and AT-125 (P <0.05), and no inhibition with azaserine. A similar modulation of PRPP pool size was demonstrated in vivo following administration of 250 mg/kg of AT-125 in mice bearing colonic adenocarcinoma lines. It was suggested that a significant increase of PRPP pool size might cause the possible synergism of a selected l-glutamine antagonist and 5-fluorouracil as reported after the appropriately scheduled administration of methotrexate and 5-fluorouracil.

AB - The intratumoral content of 5-phosphoribosyl 1-pyrophosphate (PRPP) and the acitivity of the enzymes anabolizing and catabolizing the sugar phosphate were determined following i.p. administration of an ld10 dose of an l-glutamine antagonist or saline to tumor-bearing animals. Elevation of PRPP pool size following administration of l-[αS,5S]-α-amino-3-chloro-4,5-dihydro-5-isopazoleacetic acid (NSC-163501) (AT-125) was maximal at 8 hr and returned to pretreatment levels by 24 hr. In P388 leukemia, dose for dose, at 4 hr, 6-diazo-5-oxo-l-norleucine (NSC-7365) (DON) was the most potent of the l-glutamine antagonists in elevating basal PRPP pool size (507% above control) followed by AT-125 and azaserine, 300 and 100% above control respectively. Moreover, such augmentation in PRPP pool size preferentially affected P388 tumor rather than the small intestine. Following i.p. administration of ld10 doses of AT-125, DON and azaserine, the specific activities of PRPP anabolizing and catabolizing enzymes were determined. A significant inhibition of PRPP amidotransferase was demonstrated with DON and AT-125 (P <0.05), and no inhibition with azaserine. A similar modulation of PRPP pool size was demonstrated in vivo following administration of 250 mg/kg of AT-125 in mice bearing colonic adenocarcinoma lines. It was suggested that a significant increase of PRPP pool size might cause the possible synergism of a selected l-glutamine antagonist and 5-fluorouracil as reported after the appropriately scheduled administration of methotrexate and 5-fluorouracil.

UR - http://www.scopus.com/inward/record.url?scp=0020083411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020083411&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(82)90373-2

DO - 10.1016/0006-2952(82)90373-2

M3 - Article

VL - 31

SP - 1509

EP - 1513

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 8

ER -